SEC Company Response from TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686) (TEVA) — May 26, 2010
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686)
Date: May 26, 2010 · CIK: 0000818686 · Accession: 0000899140-10-000435
AI Filing Summary & Sentiment
File numbers found in text: 000-16174
Referenced dates: May 17, 2010
Show Raw Text
CORRESP
1
filename1.htm
t5636128.htm
WILLKIE FARR & GALLAGHER llp
787 Seventh Avenue
New York, NY 10019-6099
Tel: 212 728 8000
Fax: 212 728 8111
VIA EDGAR
May 26, 2010
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant
Division of Corporation Finance
Re:
Teva Pharmaceutical Industries Limited
Form 20-F for the Fiscal Year Ended December 31, 2009
File No. 000-16174
Dear Mr. Rosenberg:
I refer to your letter dated May 17, 2010 to Eyal Desheh, Chief Financial Officer of Teva Pharmaceutical Industries Limited, regarding Teva’s Form 20-F for the Fiscal Year Ended December 31, 2009. Teva is actively working on its responses to the comments of the Staff raised in the letter and expects to submit its responses in early June.
Should any member of the Staff have any questions, please do not hesitate to call me at (212) 728-8592.
Very truly yours,
/s/ Jeffrey S. Hochman
Jeffrey S. Hochman
cc: Don Abbott (SEC)
Frank Wyman (SEC)
Eyal Desheh (Teva)
Richard S. Egosi (Teva)
Peter H. Jakes (Willkie)
New York Washington Paris London Milan Rome Frankfurt Brussels
in alliance with Dickson Minto W.S., London and Edinburgh